JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v1i1.112ArticleA Foreword from the Editorhttps://artdesignp.com/journal/JMDS/1/1/10.18063/jmds.v1i1.112BoeynaemsJean-Marie2016112016-07-21Welcome to the inaugural issue of the Journal of Medicines Development Sciences. This new open access journal will publish articles on the entire process of discovery and development of new medicinal products, with a particular emphasis on translational research. This inaugural issue is devoted to “Open Innovation”, a booming concept that is starting to deeply change the context of medicines development.

1. Chesbrough, H. W. (2003). Open Innovation: The new imperative for creating and profiting from technology. Harvard Business School Press, Boston.2. AB InBev open innovation submission portal. (n.d.). Retrieved April 8, 2015, from <https://ab-inbev.yet2.com/submission/index.jsf>3. Crowed revved up by BMW open innovation contest. (n.d.). Retrieved April 8, 2015, from <http://www.ideaconnection.com/open-innovation-success/Crowd-Revved-Up-by-BMW-Open-Innovation-Contest-00399.html>4. Khanna, I. (2012). Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discovery Today, 17(19–20), 1088–1102. http://dx.doi.org/10.1016/j.drudis.2012.05.0075. Schuhmacher, A., Germann, P. G., Gassmann, O., et al. (2013). Models for open innovation in the pharmaceutical industry. Drug Discovery Today, 18(23–24), 1133–1137. http://dx.doi.org/10.1016/j.drudis.2013.07.0136. Bianchi, M., Cavaliere, A., Chiaroni, D., et al. (2011). Organisational modes for open innovation in the bio-pharmaceutical industry: an exploratory analysis. Technovation, 31, 22–33. http://dx.doi.org/10.1016/j.technovation.2010.03.0027. Dahlem, A. M. (2012). Open innovation, networks, and strategic partnerships in drug discovery and development. Retrieved April 10, 2015, from <http://fnih.org/sites/all/files/documents/Andrew_Dahlem.pdf>8. Open innovation drug discovery. (n.d.). Retrieved April 8, 2015, from <https://openinnovation.lilly.com/dd/>9. Open innovation. (n.d.). Retrieved April 10, 2015, from <http://openinnovation.astrazeneca.com/>10. Centers for therapeutic innovation. (n.d.). Retrieved April 11, 2015, from <http://www.pfizer.com/research/rd_partnering/centers_for_therapeutic_innovation>11. GSK consumer healthcare open innovation. (n.d.). Retrieved April 11, 2015, from <http://innovation.gsk.com/innovative-product-ideas.aspx>12. Innovative medicines initiative. (n.d.). Retrieved April 10, 2015, from <http://www.imi.europa.eu/>13. Critical path institute. (n.d.). Retrieved April 15, 2015, from <http://c-path.org/>14. TransCelerate BioPharma. (n.d.). Retrieved April 16, 2015, from <http://www.transceleratebiopharmainc.com/>